Literature DB >> 30599870

A nomogram for individual prediction of vascular invasion in primary breast cancer.

Fu-Sheng Ouyang1, Bao-Liang Guo1, Xi-Yi Huang2, Li-Zhu Ouyang3, Cui-Ru Zhou1, Rong Zhang1, Mei-Lian Wu1, Zun-Shuai Yang1, Shang-Kun Wu1, Tian-di Guo1, Shao-Ming Yang4, Qiu-Gen Hu5.   

Abstract

OBJECTIVES: To explore the feasibility of preoperative prediction of vascular invasion (VI) in breast cancer patients using nomogram based on multiparametric MRI and pathological reports.
METHODS: We retrospectively collected 200 patients with confirmed breast cancer between January 2016 and January 2018. All patients underwent MRI examinations before the surgery. VI was identified by postoperative pathology. The 200 patients were randomly divided into training (n = 100) and validation datasets (n = 100) at a ratio of 1:1. Least absolute shrinkage and selection operator (LASSO) regression was used to select predictors most associated with VI of breast cancer. A nomogram was constructed to calculate the area under the curve (AUC) of receiver operating characteristics, sensitivity, specificity, accuracy, positive prediction value (PPV) and negative prediction value (NPV). We bootstrapped the data for 2000 times without setting the random seed to obtain corrected results.
RESULTS: VI was observed in 79 patients (39.5%). LASSO selected 10 predictors associated with VI. In the training dataset, the AUC for nomogram was 0.94 (95% confidence interval [CI]: 0.89-0.99, the sensitivity was 78.9% (95%CI: 72.4%-89.1%), the specificity was 95.3% (95%CI: 89.1%-100.0%), the accuracy was 86.0% (95%CI: 82.0%-92.0%), the PPV was 95.7% (95%CI: 90.0%-100.0%), and the NPV was 77.4% (95%CI: 67.8%-87.0%). In the validation dataset, the AUC for nomogram was 0.89 (95%CI: 0.83-0.95), the sensitivity was 70.3% (95%CI: 60.7%-79.2%), the specificity was 88.9% (95%CI: 80.0%-97.1%), the accuracy was 77.0% (95%CI: 70.0%-83.0%), the PPV was 91.8% (95%CI: 85.3%-98.0%), and the NPV was 62.7% (95%CI: 51.7%-74.0%). The nomogram calibration curve shows good agreement between the predicted probability and the actual probability.
CONCLUSION: The proposed nomogram could be used to predict VI in breast cancer patients, which was helpful for clinical decision-making.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Magnetic Resonance Imaging; Nomogram; Vascular invasion

Mesh:

Year:  2018        PMID: 30599870     DOI: 10.1016/j.ejrad.2018.11.013

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  DNA Methylation in Human Breast Cancer Cell Lines Adapted to High Nitric Oxide.

Authors:  Berna Demircan; Burcu Yucel; James A Radosevich
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

2.  Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer.

Authors:  Bo Bae Choi
Journal:  World J Surg Oncol       Date:  2021-03-15       Impact factor: 2.754

3.  Predicting lymphovascular invasion in clinically node-negative breast cancer detected by abbreviated magnetic resonance imaging: Transfer learning vs. radiomics.

Authors:  Bao Feng; Zhuangsheng Liu; Yu Liu; Yehang Chen; Haoyang Zhou; Enming Cui; Xiaoping Li; Xiangmeng Chen; Ronggang Li; Tianyou Yu; Ling Zhang; Wansheng Long
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

4.  Value of digital mammography in predicting lymphovascular invasion of breast cancer.

Authors:  Zhuangsheng Liu; Ruqiong Li; Keming Liang; Junhao Chen; Xiangmeng Chen; Xiaoping Li; Ronggang Li; Xin Zhang; Lilei Yi; Wansheng Long
Journal:  BMC Cancer       Date:  2020-04-03       Impact factor: 4.430

5.  Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer.

Authors:  Ma-Yi-di-Li Ni-Jia-Ti; Di-Li-A-Re-Mu Ai-Hai-Ti; Ai-Si-Ka-Er-Jiang Huo-Jia; Pa-Li-Dan-Mu Wu-Mai-Er; A-Bu-du-Ke-You-Mu-Jiang A-Bu-Li-Zi; Yu Shi; Nu-Er-A-Mi-Na Rou-Zi; Wen-Jing Su; Guo-Zhao Dai; Mai-He-Mi-Ti-Jiang Da-Mo-la
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.